CR7804A - COMBINED THERAPY FOR THE TREATMENT OF ACUTE LEUKEMIA AND MYELODISPLASIC SYNDROME - Google Patents

COMBINED THERAPY FOR THE TREATMENT OF ACUTE LEUKEMIA AND MYELODISPLASIC SYNDROME

Info

Publication number
CR7804A
CR7804A CR7804A CR7804A CR7804A CR 7804 A CR7804 A CR 7804A CR 7804 A CR7804 A CR 7804A CR 7804 A CR7804 A CR 7804A CR 7804 A CR7804 A CR 7804A
Authority
CR
Costa Rica
Prior art keywords
treatment
syndrome
myelodisplasic
acute leukemia
combined therapy
Prior art date
Application number
CR7804A
Other languages
Spanish (es)
Inventor
Jay Marshall Feingold
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR7804A publication Critical patent/CR7804A/en

Links

Classifications

    • E—FIXED CONSTRUCTIONS
    • E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
    • E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
    • E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices
    • E05F3/04—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes
    • E05F3/10—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction
    • E05F3/108—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction with piston rod protruding from the closer housing; Telescoping closers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • E—FIXED CONSTRUCTIONS
    • E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
    • E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
    • E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan metodos de tratamiento y combinaciones farmaceuticas para el tratamiento de la leucemia aguda, tales como leucemia mielogenosa aguda y sindrome displasico. Los metodos de tratamiento y combinaciones farmaceuticas emplean un conjugado citotoixico de anti-CD33 en comnbinacion con la menos un compuesto seleccionado del grupo que consiste de una antraciclina y un analogo del nucleosido de primidina o purina.Treatment methods and pharmaceutical combinations are provided for the treatment of acute leukemia, such as acute myelogenous leukemia and dysplasic syndrome. The treatment methods and pharmaceutical combinations employ an anti-CD33 cytotoxic conjugate in combination with at least one compound selected from the group consisting of an anthracycline and a primidin or purine nucleoside analog.

CR7804A 2002-11-06 2005-04-25 COMBINED THERAPY FOR THE TREATMENT OF ACUTE LEUKEMIA AND MYELODISPLASIC SYNDROME CR7804A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/035532 WO2004043461A1 (en) 2002-11-06 2002-11-06 Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome

Publications (1)

Publication Number Publication Date
CR7804A true CR7804A (en) 2008-10-29

Family

ID=32311637

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7804A CR7804A (en) 2002-11-06 2005-04-25 COMBINED THERAPY FOR THE TREATMENT OF ACUTE LEUKEMIA AND MYELODISPLASIC SYNDROME

Country Status (10)

Country Link
EP (1) EP1575582A4 (en)
JP (1) JP2006508119A (en)
CN (1) CN1720044A (en)
AU (2) AU2002348178A1 (en)
BR (1) BR0215935A (en)
CA (1) CA2504611A1 (en)
CR (1) CR7804A (en)
MX (1) MXPA05004711A (en)
NO (1) NO20052009L (en)
WO (1) WO2004043461A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050075A2 (en) * 2004-10-29 2006-05-11 Regents Of The University Of California Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents
EP1661584A1 (en) * 2004-11-26 2006-05-31 Heinz Dr. Faulstich Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy
KR20080030659A (en) * 2005-07-06 2008-04-04 카니사 파마슈티컬즈, 인크. Treatment of cancer patients using calicheamicin-antibody conjugates in combination with josquidar
ES2371085T3 (en) * 2006-05-27 2011-12-27 Faulstich, Heinz, Dr. USE OF AMATOXIN OR FALOTOXIN CONJUGATES WITH MACROMOLECULES FOR TUMOR THERAPY AND INFLAMMATION.
CN1994293A (en) * 2006-08-18 2007-07-11 上海交通大学医学院附属瑞金医院 Application of Oridonin A in Pharmaceuticals
AU2007317333A1 (en) * 2006-11-02 2008-05-15 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases
PL3300601T3 (en) * 2007-02-16 2022-05-02 Rotalec Ip Holdings Llc Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
EP2249831A2 (en) * 2007-12-10 2010-11-17 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-ý(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl¨-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
US20110159507A1 (en) 2008-08-29 2011-06-30 School Juridical Person The Kitasato Institute Method for detecting the drug effects of dna methylation-inhibitors
US12064445B2 (en) 2015-12-03 2024-08-20 Biosight Ltd. Cytarabine conjugates for cancer therapy
US12071450B2 (en) 2015-12-03 2024-08-27 Biosight Ltd. Salts of conjugates for cancer therapy
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
WO2017210621A1 (en) * 2016-06-03 2017-12-07 Seattle Genetics, Inc. Combination of cd33 antibody drug conjugates with chemotherapeutic agents
WO2017214433A1 (en) 2016-06-09 2017-12-14 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
AR112202A1 (en) * 2017-06-22 2019-10-02 Servier Lab COMBINATION OF A MCL-1 INHIBITOR AND A STANDARD CARE TREATMENT FOR HEMATOLOGICAL CANCERS, USES AND PHARMACEUTICAL COMPOSITIONS OF THIS
CA3069558A1 (en) * 2017-07-09 2019-01-17 Biosight Ltd. Combination cancer therapy
IL285155B2 (en) * 2019-01-28 2026-01-01 Univ Texas Metal chelator combination therapy for the treatment of cancer
CN110123825B (en) * 2019-05-28 2021-11-30 宁波市鄞州人民医院 Pharmaceutical composition containing demethoxydaunorubicin
WO2022093983A1 (en) * 2020-10-27 2022-05-05 Vor Biopharma, Inc. Compositions and methods for treating hematopoietic malignancy
WO2025214401A1 (en) * 2024-04-12 2025-10-16 四川科伦博泰生物医药股份有限公司 Antibody-drug conjugate, composition, and use thereof and method therefor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
CA2418014C (en) * 2000-08-08 2014-01-21 Immunomedics, Inc. Immunotherapy for chronic myelocytic leukemia

Also Published As

Publication number Publication date
WO2004043461A1 (en) 2004-05-27
NO20052009D0 (en) 2005-04-25
NO20052009L (en) 2005-06-27
CN1720044A (en) 2006-01-11
CA2504611A1 (en) 2004-05-27
AU2002348178A1 (en) 2004-06-03
BR0215935A (en) 2005-08-09
EP1575582A4 (en) 2009-03-11
EP1575582A1 (en) 2005-09-21
MXPA05004711A (en) 2005-08-03
AU2010201113A1 (en) 2010-04-15
JP2006508119A (en) 2006-03-09

Similar Documents

Publication Publication Date Title
CR7804A (en) COMBINED THERAPY FOR THE TREATMENT OF ACUTE LEUKEMIA AND MYELODISPLASIC SYNDROME
AR027355A1 (en) THIAZOLIDINCARBOXILIC ACIDS
ECSP105178A (en) ARIL UREA COMPOUNDS IN COMBINATION WITH OTHER CITTATIC OR CYTOTOXIC AGENTS FOR CANCER TREATMENT IN HUMANS
CL2008002139A1 (en) Dimer compounds derived from pyrrolo [2,1c] [1,4] benzodiazepine-5 -one (tomaimycin), a conjugate comprising them; procedure of preparation of conjugates; pharmaceutical composition comprising the compounds or conjugates; and use of compounds and conjugates in the treatment of cancer.
CL2003002786A1 (en) LIOFILIZED COMPOSITION THAT INCLUDES I) AN EPOTILONE AND II) MANITOL OR A CYCLODEXTRINE AND LIOFILIZED COMPOSITION THAT INCLUDES THEM RECONSTITUTED WITH SOLVENT, USED AS A CYTOTOXIC IN TUMOR TREATMENT.
UY27943A1 (en) COMPOSITIONS AND METHODS TO TREAT CRNCER USING ANTIBODY IMMUNOCATE PLAYS FOR CD44 CYTOTNXICS AND CHEMOTHERAPCUTIC AGENTS
MX2021015992A (en) AZACITIDINE IN COMBINATION WITH VENETOCLAX, GILTERITINIB, MIDOSTAURINE OR OTHER COMPOUNDS FOR THE TREATMENT OF LEUKEMIA OR MYELODYSPLASTIC SYNDROME.
CR11687A (en) COMBINATION THERAPY OF AN ANTI-CD20 TYPE II ANTIBODY WITH INCREASED ANTIBODY CELLULAR CYTOTOXICITY (CCDA)
MX2019010879A (en) CANCER TREATMENT.
GT200600517A (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
CL2009001170A1 (en) Pharmaceutical composition for oral administration comprising immediate release 5-azacitidine without enteric coating; and its use for the treatment of a disease associated with abnormal cell proliferation, such as myelodysplastic syndrome, acute myelogenous leukemia and lung cancer, among others.
ECSP045407A (en) BENZAZOLES SUBSTITUTED AND THE USE OF THE SAME AS INHIBITORS OF QUINASA RAF
AR013269A1 (en) PRODUCT CONTAINING AT LEAST A DOUBLE FILAMENT RNA COMBINED WITH AT LEAST AN ANTI-VIRAL AGENT, FOR THERAPEUTIC USE IN THE TREATMENT OF A VIRAL DISEASE, ESPECIALLY OF VIRAL HEPATITIS
CL2008001103A1 (en) Compounds derived from [1,2,3] triazolo [4,5-b] pyridine-corboxamides and [1,2,3] triazolo [4,5-d] pyrimidine-carboxamides, megl and faah inhibitors; preparation procedure; pharmaceutical composition; and its use in the treatment of acute or chronic pain, vertigo, vomiting, nausea, metabolic syndrome, dyslipidemia, among others.
WO2004087713A8 (en) Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
ES2572454T3 (en) Treatment of diseases mediated by T lymphocytes
WO2008101214A3 (en) Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
AR047988A1 (en) ANTI -OPLASTIC COMBINATIONS OF CCI-779 AND RITUXIMAB
AR051405A1 (en) 2-CARBOXAMIDE (3-AMINO) THIOPHENE COMPOUNDS
ECSP034766A (en) A COMBINATION THAT INCLUDES COMBRETASTATINE AND ANTI-BANERIGINAL AGENTS
SV2009003403A (en) EXTRUDED WITH IMPROVED FLAVOR MASK
WO2007087631A3 (en) Cobalamin compositions for the treatment of cancer
ECSP11011363A (en) DERIVATIVES OF QUINOXALINE AND ITS USE FOR THE TREATMENT OF BENIGN AND EVIL TUMORS
EA200300427A1 (en) ANTI-TUMOR THERAPY, INCLUDING DERIVATAMIC DERIVATIVES
ITRM20030194A0 (en) USE OF 7-NITRO-2,1,3-BENZOXADIAZOLE DERIVATIVES FOR THE THERAPY OF TUMOR FORMS.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)